Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Liver Cirrhosis Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Liver Cirrhosis Overview | 9 | 1 |
| Pipeline Products for Liver Cirrhosis Comparative Analysis | 10 | 1 |
| Liver Cirrhosis Therapeutics under Development by Companies | 11 | 1 |
| Liver Cirrhosis Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Liver Cirrhosis Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Liver Cirrhosis Products under Development by Companies | 16 | 1 |
| Liver Cirrhosis Products under Investigation by Universities/Institutes | 17 | 1 |
| Liver Cirrhosis Companies Involved in Therapeutics Development | 18 | 9 |
| Conatus Pharmaceuticals Inc. | 18 | 1 |
| Digna Biotech, S.L. | 19 | 1 |
| Galectin Therapeutics, Inc. | 20 | 1 |
| Human Stem Cells Institute | 21 | 1 |
| Nimbus Therapeutics, LLC | 22 | 1 |
| Ocera Therapeutics, Inc. | 23 | 1 |
| Pharmicell Co., Ltd. | 24 | 1 |
| S-Evans Biosciences, Inc. | 25 | 1 |
| Stelic Institute &Co., Inc. | 26 | 1 |
| Liver Cirrhosis Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 35 |
| Cellgram-LC Drug Profile | 36 | 1 |
| DB-027 Drug Profile | 37 | 1 |
| DB-036 Drug Profile | 38 | 1 |
| emricasan Drug Profile | 39 | 6 |
| Gemacell Drug Profile | 45 | 1 |
| GRMD-02 Drug Profile | 46 | 11 |
| GXHPC-1 Drug Profile | 57 | 1 |
| ND-654 Drug Profile | 58 | 2 |
| ornithine phenylacetate Drug Profile | 60 | 5 |
| Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis Drug Profile | 65 | 1 |
| Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis Drug Profile | 66 | 1 |
| Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis Drug Profile | 67 | 1 |
| Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis Drug Profile | 68 | 1 |
| Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders Drug Profile | 69 | 1 |
| STNM-04 Drug Profile | 70 | 1 |
| Liver Cirrhosis Dormant Projects | 71 | 1 |
| Liver Cirrhosis Discontinued Products | 72 | 1 |
| Liver Cirrhosis Product Development Milestones | 73 | 12 |
| Featured News &Press Releases | 73 | 1 |
| May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial | 73 | 1 |
| Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data | 74 | 1 |
| Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting | 75 | 1 |
| Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial | 76 | 1 |
| Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting | 77 | 1 |
| Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting | 78 | 1 |
| Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting | 78 | 1 |
| Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting | 79 | 1 |
| Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement | 79 | 2 |
| May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam | 81 | 1 |
| Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting | 82 | 1 |
| Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting | 83 | 1 |
| Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension | 83 | 1 |
| Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis | 84 | 1 |
| Appendix | 85 | 2 |
| Methodology | 85 | 1 |
| Coverage | 85 | 1 |
| Secondary Research | 85 | 1 |
| Primary Research | 85 | 1 |
| Expert Panel Validation | 85 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 86 | 1 |